Human cytomegalovirus (HCMV) induces telomerase expression in both normal and malignant human cells, stimulating cell proliferation and immortalization. Additionally, a dietary supplement containing selenium, vitamin E, and beta-carotene reduces gastric cancer and overall mortality in individuals taking the supplements.
A population-based study found that HPV16 and HPV18 genotypes were present in the majority of invasive cervical cancers in New Mexico. The mean age of women diagnosed with HPV16- or HPV18-positive cancer was 5 years younger than that of women diagnosed with other HPV types, suggesting implications for future cancer screening.
A randomized controlled trial found that a 3-drug chemotherapy combination of docetaxel, cisplatin, and 5-fluorouracil (TPF) increased organ preservation rates in patients with locally advanced larynx cancer. Compared to the single-agent TPF, the addition of docetaxel improved larynx function and overall response rates.
Daily folic acid supplements may increase prostate cancer risk by more than twice that of placebo. Baseline dietary folate intake and plasma levels showed a trend towards reduced risk but did not reach statistical significance. Researchers suggest large epidemiological studies using improved methods to study diet and cancer prevention.
Systematic literature reviews and meta-analyses support the use of risk assessment models combined with breast density information to identify high-risk postmenopausal women. Lifestyle factors such as exercise, weight reduction, and reduced alcohol intake also show promise in reducing breast cancer risk.
Researchers found that study methods and definitions of lead time significantly impact estimates of prostate cancer screening's effectiveness. The study suggests a need for clear methodology to accurately interpret findings.
A Million Women Study found that low to moderate alcohol consumption among women increases cancer risk for breast, liver, rectum, and upper aero-digestive tract cancers. The risk is highest after one drink per day, with an excess of about 15 cancers per 1000 women.
A new study found that goserelin treatment reduced the risk of disease recurrence and deaths by 13.9% and 8.5% respectively in premenopausal women with early breast cancer. The benefits were comparable to those seen with tamoxifen treatment, suggesting goserelin may be a viable alternative for some patients.
A recent study found that socioeconomic status is linked to an increased risk of developing lung cancer, with Europeans having lower education levels experiencing a higher incidence. The research suggests that while smoking accounts for approximately half of this risk, diet and other factors also play a role in the disparity.
Researchers found that gene expression profiles differed between tumor samples from patients who had taken vitamin E, selenium, or both supplements compared to those on placebo. The study provides insight into the effects of preoperative supplement use on prostate cancer gene expression, a potential area for future investigation.
A study found that lack of general treatment failure and distant metastases 3 years after treatment initiation may be surrogate endpoints for long-term survival in early prostate cancer patients. Another study identified netrin-1 as a potential therapeutic target for non-small cell lung cancer.
Patients with relapsed follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than those without treatment. Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment.
A study found a potential genetic link between a germ-line mutation in the TTF-1 gene and an increased risk of developing multi-nodular goiter (MNG) and papillary thyroid cancer (PTC). The researchers also explored the effects of early mammography on breast cancer risk in BRCA mutation carriers.
A randomized controlled trial found that alternating cycles of chemotherapy and radiation have similar outcomes to sequential chemotherapy followed by radiation in treating larynx cancer. The study showed no significant difference in clinical outcomes between the two treatment groups.
A study published in the Journal of the National Cancer Institute found that HPV18 DNA levels are not associated with the likelihood of progressing to advanced precancerous lesions of the cervix. The study suggests that testing for high levels of HPV18 DNA is not clinically useful.
Researchers examined the link between mobile phone use and uveal melanoma in a large study of 1,453 participants. No significant increased risk was found among regular users or those who used radio sets, suggesting that phone use may not be associated with this type of eye cancer.
A meta-analysis of 10 studies confirms that risk-reducing salpingo-oophorectomy significantly reduces the risk of breast and ovarian cancers in women with BRCA mutations. The procedure is associated with a 51% relative reduction in breast cancer risk and an 79% relative reduction in ovarian cancer risk.
A new study suggests that combining HPV DNA testing with cytology and repeat HPV testing can increase cervical cancer screening detection rates without a substantial increase in false-positive tests. This approach resulted in a 30% higher detection rate compared to cytology alone, while doubling the number of required tests.
Researchers found that lapatinib delayed tumor development and reduced the number of tumors in a mouse model of hormone receptor-negative breast cancer. Lapatinib is a small-molecule inhibitor that blocks tyrosine kinase activities associated with tumor formation.
A comprehensive review of 241 gene variants and cancer risk identified only two statistically significant associations, including an XRCC1 allele and ERCC2 allele linked to lung cancer. The findings suggest that genetic risks are typically modest, and large-scale evidence is needed to establish specific associations.
A randomized controlled trial found that women taking vitamin C, E, or beta carotene had a similar risk of cancer as those not taking the supplements. Antioxidant supplements were previously thought to lower cancer risk due to high fruit and vegetable intake, but this study contradicts those findings.
Research suggests cisplatin ototoxicity is due to higher platinum concentration in inner ear, while high insulin levels are an independent risk factor for breast cancer. Studies found significant correlations between fasting insulin and increased breast cancer risk.
Two studies estimate the economic burden of cancer mortality using lost years of work and willingness-to-pay approaches. The estimated cost of cancer mortality in the US is high, with lung cancer accounting for 25% or more of costs.
Researchers found that among women under 40, black women have a higher breast cancer incidence rate than white women. However, this trend reverses among women over 40, with white women having a higher incidence rate. The study confirms the age-related crossover effect in breast cancer incidence rates between black and white ethnic groups.
A meta-analysis of 128 clinical trials has found that nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced breast cancer. The use of these regimens led to a significant relative risk reduction in overall mortality.
Researchers analyzed data from 13 prospective studies involving over half a million participants and found no link between fat, protein, or meat intake and kidney cancer. The study's findings suggest that the cause of increasing kidney cancer incidence worldwide remains unclear.
A tracking and feedback system reduced racial disparities in adjuvant therapy among women with early-stage breast cancer, increasing consultations with medical oncologists by 14 percentage points. The study found a decrease in underuse of adjuvant treatment, particularly among black and Hispanic women.
According to a recent report, cancer incidence and mortality have declined in the US for the first time among both men and women. The decline is attributed to decreases in the most common cancers, including prostate, lung, and colorectal cancer.
A randomized trial found that systematic pelvic lymphadenectomy did not improve disease-free or overall survival in women with stage I endometrial cancer. Lymphadenectomy was associated with improved surgical staging and detection of disease spread to pelvic lymph nodes, but no therapeutic benefit.
A randomized trial of over 36,000 postmenopausal women found no association between calcium and vitamin D supplementation and reduced breast cancer risk. The findings challenge previous observational studies suggesting a potential link between vitamin D levels and breast cancer incidence.
A recent study discovered that the Overexpressed in Lung Cancer 1 (OLC1) gene is consistently expressed at high levels in most lung cancers, particularly in smokers. OLC1 overexpression was also shown to induce tumor formation in tissue culture cells and mouse models of lung cancer.
Better designed rodent trials could reduce the cost and time required for cancer drug development. A well-designed rodent study should include an appropriate animal model, correct statistical evaluation of data, proper randomization, and a sufficient number of animals.
A recent study found that statin use is associated with a decline in prostate-specific antigen (PSA) levels, suggesting potential benefits for prostate cancer screening and management. The study, which analyzed data from over 1,200 men, showed a median decline of 4.1% in PSA levels after starting statin therapy.
Research found skewed X inactivation in women with BRCA1 gene mutations, associated with a later onset of breast or ovarian cancer. The Impact of Cancer scale was also refined and validated, providing a tool to measure long-term psychosocial impact on cancer survivors.
Researchers propose a nested case-control study design called PRoBE to evaluate biomarker classification accuracy, minimizing bias. Regular NSAID use is associated with a 12% relative risk reduction in breast cancer risk, according to a meta-analysis of 38 studies involving 2,788,715 women.
A subset analysis of a randomized trial found that older patients with renal cell carcinoma derive similar clinical benefits from sorafenib therapy as younger patients, including improved progression-free survival and quality of life. The treatment was well-tolerated regardless of age, with manageable side effects.
A study published in the Journal of the National Cancer Institute found that tamoxifen treatment may advance detection of ER-negative breast cancer in high-risk women, shortening the time to diagnosis by approximately 1 year. The drug does not alter the risk of ER-positive disease.
A recent observational study published in the Journal of the National Cancer Institute suggests that hormone therapy may be safe for postmenopausal women with BRCA mutations. The study found a 42% relative reduction in breast cancer risk among women who used hormone therapy, although further research is needed to confirm these findings.
Researchers developed a preoperative endocrine prognostic index (PEPI) to predict relapse risk in women with stage 2 or 3 estrogen receptor-positive breast cancer. The model incorporates tumor characteristics and is statistically significant in predicting relapse-free survival.
The breast cancer incidence in China is expected to increase due to lifestyle changes and adoption of Western lifestyles. Researchers predict a total of 2.5 million cases by 2012, with modifications to lifestyle and reproductive risk factors potentially preventing 270,000 cases.
A study adjusting for a known bias in familial melanoma risk estimates reveals an increased relative risk of 3.18, with higher risks for young-onset cases. In contrast, the risks for colorectal, lung, breast, and prostate cancer remain relatively stable.
A study published in the Journal of the National Cancer Institute found that only 38 percent of U.S. hospitals were compliant with the guideline to examine 12 or more lymph nodes in colon cancer patients by 2004-2005, despite being recommended since 1997. Compliance increased from 15% to 38% over the eight-year period.
Advances in treatment have led to increased long-term survival for US children diagnosed with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma. Period analysis reveals improved survival rates between 1990 and 2004, with projections suggesting continued progress through molecularly targeted therapies.
Regular breast cancer screening programs in developed countries show promise for reducing mortality in India. A new study estimates that annual or biennial clinical breast exams can lower mortality rates by 8.2% and gain life years at a cost-effectiveness of $1,135 per life-year gained.
A study found that individuals with a history of nonmelanoma skin cancer are at two-fold increased risk of developing subsequent cancers, including basal cell and squamous cell carcinoma. The association was strongest in younger participants, suggesting a possible inherited predisposition to cancer.
Researchers found a significant association between ACE inhibitor and ARB use and reduced incidence of basal cell carcinoma and squamous cell cancers in U.S. veterans. The study revealed a 39% relative reduction in basal cell cancer and 33% relative reduction in squamous cell cancers among users compared to non-users.
A novel multi-arm trial design could test several therapies simultaneously, speeding up cancer drug development. A natural chemical called candidaspongiolide inhibits protein synthesis and kills cancer cells through an unusual biochemical pathway.
A randomized trial found that radical prostatectomy reduces prostate cancer death rates, with benefits lasting beyond 10 years. However, the applicability of these results to modern prostate cancer patients is unclear due to the widespread use of PSA screening.
Researchers identified specific HBV genotypes and mutations associated with increased liver cancer risk, including genotype C and basal core promoter mutation A1762T/G1764A. A combination of doxorubicin and zoledronic acid was found to reduce tumor size substantially in a mouse model of breast cancer.
Despite five years of systemic therapy, breast cancer patients remain at risk for disease recurrence. Women with hormone receptor-positive cancer have a higher risk of relapse, highlighting an unmet clinical need for new strategies to reduce this risk.